Inmed Pharmaceuticals Inc. (INM) fundamentals score
Inmed Pharmaceuticals is a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.2 out of 10, Weak long-term fundamentals
- Growth: 3.2/10
- Profitability: 1.8/10
- Financial health: 6.8/10
- Earnings quality: 6.8/10
- Valuation: 3.5/10
Scores are calculated from Inmed Pharmaceuticals Inc.’s SEC filings, using the 12 months through 2025-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10